Prelude Capital Management’s Trinity Biotech TRIB Stock Holding History

Prelude Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,180	Closed	-$95K	–	1857
2017 Q1	$95K	Buy	+3,180	New	+$99.4K	0.01%	800
2016 Q4	–	Sell	-6,875	Closed	-$454K	–	1778
2016 Q3	$454K	Buy	6,875 +3,420	+99%	+$213K	0.05%	331
2016 Q2	$196K	Sell	3,455 -100	-3%	-$5.64K	0.03%	504
2016 Q1	$207K	Hold	3,555	–	–	0.03%	541
2015 Q4	$209K	Buy	3,555 +1,000	+39%	+$59K	0.03%	545
2015 Q3	$146K	Sell	2,555 -3,182	-55%	-$256K	0.02%	720
2015 Q2	$518K	Hold	5,737	–	–	0.07%	301
2015 Q1	$552K	Sell	5,737 -1,640	-22%	-$152K	0.08%	307
2014 Q4	$646K	Sell	7,377 -12,428	-63%	-$1.07M	0.09%	240
2014 Q3	$1.81M	Buy	19,805 +2,787	+16%	+$302K	0.25%	76
2014 Q2	$1.96M	Buy	17,018 +4,118	+32%	+$488K	0.26%	72
2014 Q1	$1.56M	Buy	12,900 +5,700	+79%	+$747K	0.21%	103
2013 Q4	$905K	Buy	+7,200	New	+$864K	0.15%	167
2013 Q3	–	Sell	-6,186	Closed	-$521K	–	1836
2013 Q2	$521K	Buy	+6,186	New	+$513K	0.11%	242

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Prelude Capital Management's TRIB Position: Q2 2017 in Review

Prelude Capital Management sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 3,180 shares — an estimated $95K sold.

Prelude Capital Management first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $1.96M in Q2 2014. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

Prelude Capital Management reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
Prelude Capital Management sold 3,180 Trinity Biotech shares in Q2 2017, an estimated $95K.
Prelude Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
Prelude Capital Management's Trinity Biotech position peaked at $1.96M in Q2 2014.
56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.